Herantis Pharma R&D Investor Day Highlights
Herantis Pharma Plc, Company release, 8 June 2021 at 11:00 EEST “We are delighted to host this R&D Day event, and very much look forward to providing an update on the new Herantis as a pure play CNS company and our programs fully focused on disease modifying therapeutics to address the unmet need in Parkinson’s Disease and other neurological illnesses”, commented Dr. Craig Cook, CEO of Herantis. “We are at a key juncture for the company, with solid fundamentals, fascinating science, exciting and meaningful data as we enter the next chapter for the company and our xCDNF and CDNF assets.